根据世界卫生组织(WHO)的分类,PH分为五类,其中WHO 2类肺动脉高压又称为与左心疾病相关的PH,是最常见的亚型之一。本文将重点讨论WHO 2类肺动脉高压的定义、病因、临床表现、诊断和治疗方法。 定义:WHO 2类肺动脉高压是指由于左心疾病导致的肺动脉高压。左心疾病包括各种心脏病和心血管疾病,如心肌梗死、心力衰竭...
WHO Group 1 pulmonary arterial hypertension: current and investigative therapies. Progress in cardiovascular diseases. 2012;55(2):89-103.Ventetuolo CE,Klinger JR.WHO Group 1pulmonary arterialhypertension:current and investigative therapies.Progress in Cardiovascular Diseases. 2012...
World Health Organization (WHO) group 5 pulmonary hypertension (PH) entails a heterogeneous group of disorders that may cause PH by unclear and/or multiple mechanisms. In particular, group 5 includes PH caused by hematologic disorders, systemic diseases, metabolic disorders, chronic renal failure, an...
Five main groups of pulmonary hypertension are recognized, all defined by a mean pulmonary artery pressure of >20 mmHg: pulmonary arterial hypertension (rare), pulmonary hypertension associated with left-sided heart disease (very common), pulmonary hypertension associated with lung disease (common),...
GroupHemodynamic 1. Pulmonary arterial hypertensionPrecapillary PH 1.1 Idiopathic PAH 1.2 Heritable PAH 1.2.1 BMPR2 1.2.2 ALK-1, ENG, SMAD9, CAV1, KCNK3 1.2.3 Unknown 1.3 Drug- and toxin-inuced 1.4 Associated with 1.4.1 Connective tissue disease ...
Pulmonary arterial hypertension (PAH; WHO Group 1) to improve exercise ability. Studies with TYVASO establishing effectiveness predominately included patients with NYHA Functional Class III symptoms and etiologies of idiopathic or heritable PAH (56%) or PAH associated with connective tissue diseases (33...
Major advances have been made in the treatment of World Health Organization Group 1 pulmonary arterial hypertension (PAH). Since the mid-1990s, nine medications have become available in the United States to target three key pathophysiologic derangements in PAH – the prostacyclin, endothelin, and nit...
Pulmonary Arterial Hypertension (PAH)Management of adults with PAH (WHO group 1 pulmonary hypertension) to improve exercise capacity and delay clinical worsening.Parenteral preparation used for continued treatment in patients with PAH who are temporarily unable to take oral medication....
[6] Prins KW, et al. WHO Group I Pulmonary Hypertension: Epidemiology and Pathophysiology. Cardiol Clin 2016; 34(3):363 74. [7] Humbert M, et al. Pulmonary Arterial Hypertension in France. Am J Respir Crit Care Med 2006; 173:1023 30. ...
PHuman – created in partnership with the PH patient community and dedicated to supporting people living with pulmonary arterial hypertension. Read more Related Stories Five things we know about pulmonary arterial hypertension Read more Three smart tech tools that help diagnose PAH...